A Prospective Phase II Trial of Radioembolization for Treatment of Uveal Melanoma Hepatic Metastasis.
Diagnostic Imaging
/ methods
Embolization, Therapeutic
/ methods
Female
Humans
Liver
/ diagnostic imaging
Liver Neoplasms
/ diagnostic imaging
Male
Melanoma
/ pathology
Middle Aged
Neoplasms, Second Primary
/ diagnostic imaging
Prospective Studies
Treatment Outcome
Uveal Neoplasms
/ pathology
Yttrium Radioisotopes
/ therapeutic use
Journal
Radiology
ISSN: 1527-1315
Titre abrégé: Radiology
Pays: United States
ID NLM: 0401260
Informations de publication
Date de publication:
10 2019
10 2019
Historique:
pubmed:
28
8
2019
medline:
11
3
2020
entrez:
28
8
2019
Statut:
ppublish
Résumé
Background Overall survival (OS) for patients with uveal melanoma (UM) hepatic metastases is extremely poor. Therefore, stabilization of hepatic metastases is essential to prolonging OS. Purpose To assess the safety and effectiveness of radioembolization (RE) for treatment of UM hepatic metastases. Materials and Methods Enrollment for this prospective phase II trial began November 2011 and concluded January 2017. Treatment-naïve participants (group A) and participants who progressed after immunoembolization (group B) with hepatic tumor burden less than 50% underwent RE. Participants were followed for 1 month and every 3 months for acute and delayed toxicities, respectively. MRI, CT, and PET were performed every 3 months to evaluate for tumor response and extrahepatic disease. Participants were followed for at least 2 years or until death. Kaplan-Meier method and multivariable Cox proportional hazard models were used for data analysis. Results In group A, 24 participants (mean age ± standard deviation, 59 years ± 13; 13 men and 11 women) underwent unilobar (
Identifiants
pubmed: 31453767
doi: 10.1148/radiol.2019190199
pmc: PMC6776232
doi:
Substances chimiques
Yttrium Radioisotopes
0
Types de publication
Clinical Trial, Phase II
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
223-231Références
Radiology. 2009 Jul;252(1):290-8
pubmed: 19561263
Cardiovasc Intervent Radiol. 2017 Jun;40(6):864-872
pubmed: 28144756
Cancer. 1995 Nov 1;76(9):1665-70
pubmed: 8635073
Int J Cancer. 2014 Mar 1;134(5):1207-13
pubmed: 23934701
J Clin Oncol. 2008 Nov 20;26(33):5436-42
pubmed: 18838710
J Vasc Interv Radiol. 2018 Oct;29(10):1369-1375
pubmed: 30174161
Am J Clin Oncol. 2016 Apr;39(2):189-95
pubmed: 24441583
Exp Mol Med. 2017 Jul 21;49(7):e359
pubmed: 28729640
J Surg Oncol. 2018 May;117(6):1170-1178
pubmed: 29284076
Eur J Radiol. 2010 Jun;74(3):e38-44
pubmed: 19467811
Ther Adv Med Oncol. 2018 Feb 21;10:1758834018757175
pubmed: 29497459
Ocul Oncol Pathol. 2018 Apr;4(3):145-151
pubmed: 29765944
Cancer Invest. 2009 Jul;27(6):682-90
pubmed: 19219675
Curr Oncol Rep. 2017 Jul;19(7):45
pubmed: 28508938
J Vasc Interv Radiol. 2006 Aug;17(8):1251-78
pubmed: 16923973
J Vasc Interv Radiol. 2015 Apr;26(4):523-32.e2
pubmed: 25678394
Ophthalmology. 2003 May;110(5):962-5
pubmed: 12750098
Cardiovasc Intervent Radiol. 2013 Feb;36(1):158-65
pubmed: 22526099
J Vasc Interv Radiol. 2003 Sep;14(9 Pt 2):S199-202
pubmed: 14514818
Oncol Ther. 2018 Jun;6(1):87-104
pubmed: 32700136
AJR Am J Roentgenol. 2011 Feb;196(2):468-73
pubmed: 21257902
EBioMedicine. 2015 Sep 18;2(11):1821-6
pubmed: 26870807
Biometrics. 1985 Sep;41(3):741-4
pubmed: 4074823
J Natl Cancer Inst. 2000 Feb 2;92(3):205-16
pubmed: 10655437
J Cancer Res Clin Oncol. 2007 Mar;133(3):177-84
pubmed: 17021903
Semin Radiat Oncol. 2003 Jul;13(3):176-81
pubmed: 12903007